| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 8 | | | |
| | | | | 12 | | | |
| | | | | 21 | | | |
| | | | | 23 | | | |
| | | | | 29 | | | |
| | | | | 35 | | | |
| | | | | 42 | | | |
| | | | | 52 | | | |
| | | | | 53 | | | |
| | | | | 55 | | | |
| | | | | 56 | | | |
| | | | | 57 | | | |
| | | | | 59 | | | |
| | | | | 62 | | | |
| | | | | 63 | | | |
| | | | | 63 | | | |
| | | | | 64 | | | |
| | | | | A-1 | | | |
| | | | | B-1 | | |
Name
|
| |
Age
|
| |
Present Position with Catabasis Pharmaceuticals, Inc.
|
|
Gregg Lapointe
|
| | 62 | | | Director | |
Jonathan Violin
|
| | 45 | | | Director | |
Name
|
| |
Age
|
| |
Present Position with Catabasis Pharmaceuticals, Inc.
|
|
Fred Callori
|
| | 53 | | | Director | |
Michael Kishbauch
|
| | 72 | | | Director | |
Jill Milne
|
| | 53 | | | President, Chief Executive Officer and Director | |
Name
|
| |
Age
|
| |
Present Position with Catabasis Pharmaceuticals, Inc.
|
|
Kenneth Bate
|
| | 70 | | | Director, Chair of the Board of Directors | |
Joanne Beck
|
| | 60 | | | Director | |
Hugh Cole
|
| | 56 | | | Director | |
| Actinium Pharmaceuticals | | | Catalyst Biosciences | | | Marinus Pharmaceuticals | |
| Akari Therapeutics | | | Chiasma | | | Matinas BioPharma | |
| Allena Pharmaceuticals | | | Cidara Therapeutics | | | Ovid Therapeutics | |
| Anavex Pharmaceuticals | | | Eiger BioPharmaceuticals | | | Proteostasis Therapeutics | |
| Aridis Pharmaceuticals | | | Entasis Therapeutics | | | Pulmatix | |
| aTyr Pharma | | | Eyenovia | | | Trevena | |
Name
|
| |
Fees Earned or
Paid In Cash ($) |
| |
Option
Awards ($)(1) |
| |
Total ($)
|
| |||||||||
Kenneth Bate
|
| | | | 85,000 | | | | | | 29,443 | | | | | | 114,443 | | |
Burt Adelman, M.D.
|
| | | | 45,000 | | | | | | 29,443 | | | | | | 74,443 | | |
Joanne Beck
|
| | | | 45,000 | | | | | | 29,443 | | | | | | 74,443 | | |
Hugh Cole
|
| | | | 42,500 | | | | | | 29,443 | | | | | | 71,943 | | |
Michael Kishbauch
|
| | | | 48,750 | | | | | | 29,443 | | | | | | 78,193 | | |
Gregg Lapointe
|
| | | | 55,000 | | | | | | 29,443 | | | | | | 84,443 | | |
| | |
Member
Annual Fee |
| |
Chair Incremental
Annual Fee |
| ||||||
Board of Directors
|
| | | $ | 35,000 | | | | | $ | 35,000 | | |
Audit Committee
|
| | | $ | 7,500 | | | | | $ | 12,500 | | |
Compensation Committee
|
| | | $ | 5,000 | | | | | $ | 5,000 | | |
Nominating and Corporate Governance Committee
|
| | | $ | 3,750 | | | | | $ | 3,750 | | |
Science and Technology Committee
|
| | | $ | 5,000 | | | | | $ | 5,000 | | |
Name
|
| |
Age
|
| |
Position(s)
|
|
Jill Milne, Ph. D.
|
| |
53
|
| | President and Chief Executive Officer, Director | |
Noah Clauser
|
| |
48
|
| | Chief Financial Officer | |
Joanne Donovan, M.D., Ph. D.
|
| |
64
|
| | Chief Medical Officer | |
Benjamin Harshbarger
|
| |
52
|
| | General Counsel | |
Andrew Nichols, Ph. D.
|
| |
60
|
| | Chief Scientific Officer | |
Andrew Komjathy
|
| |
58
|
| | Chief Commercial Officer | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($)(1) |
| |
Option
Awards ($)(2) |
| |
All Other
Compensation ($)(3) |
| |
Total
($) |
| ||||||||||||||||||
Jill C. Milne, Ph.D.
President and Chief Executive Officer |
| | | | 2020 | | | | | | 519,925 | | | | | | 194,972 | | | | | | 535,341 | | | | | | 2,063 | | | | | | 1,252,301 | | |
| | | 2019 | | | | | | 500,891 | | | | | | 231,662 | | | | | | 298,253 | | | | | | 1,991 | | | | | | 1,032,797 | | | ||
Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer |
| | | | 2020 | | | | | | 436,497 | | | | | | 192,774 | | | | | | 214,136 | | | | | | 2,222 | | | | | | 845,629 | | |
| | | 2019 | | | | | | 423,783 | | | | | | 168,454 | | | | | | 119,301 | | | | | | 2,172 | | | | | | 713,710 | | | ||
Andrew Nichols, Ph.D.
Chief Scientific Officer |
| | | | 2020 | | | | | | 378,958 | | | | | | 163,161 | | | | | | 214,136 | | | | | | 2,116 | | | | | | 758,371 | | |
| | | 2019 | | | | | | 367,920 | | | | | | 142,569 | | | | | | 119,301 | | | | | | 2,155 | | | | | | 631,945 | | |
| | |
Option Awards
|
| |||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
Jill C. Milne, Ph.D.
|
| | | | 8,427 | | | | | | — | | | | | $ | 16.70 | | | | | | 2/28/2021 | | |
| | | | | 2,229 | | | | | | — | | | | | $ | 23.10 | | | | | | 12/17/2022 | | |
| | | | | 3,247 | | | | | | — | | | | | $ | 23.10 | | | | | | 12/17/2022 | | |
| | | | | 2,860 | | | | | | — | | | | | $ | 23.10 | | | | | | 4/16/2023 | | |
| | | | | 5,836 | | | | | | — | | | | | $ | 68.10 | | | | | | 3/18/2024 | | |
| | | | | 933 | | | | | | — | | | | | $ | 110.50 | | | | | | 3/25/2025 | | |
| | | | | 16,000 | | | | | | — | | | | | $ | 140.50 | | | | | | 7/16/2025 | | |
| | | | | 10,300 | | | | | | — | | | | | $ | 45.70 | | | | | | 2/10/2026 | | |
| | | | | 4,500 | | | | | | — | | | | | $ | 43.10 | | | | | | 9/7/2026 | | |
| | | | | 19,168 | | | | | | 832(1) | | | | | $ | 12.40 | | | | | | 2/8/2027 | | |
| | | | | 16,292 | | | | | | 6,708(2) | | | | | $ | 12.80 | | | | | | 2/7/2028 | | |
| | | | | 23,000 | | | | | | — | | | | | $ | 7.10 | | | | | | 9/6/2028 | | |
| | | | | 45,833 | | | | | | 54,167(3) | | | | | $ | 4.39 | | | | | | 2/12/2029 | | |
| | | | | — | | | | | | 150,000(4) | | | | | $ | 5.32 | | | | | | 2/11/2030 | | |
Joanne M. Donovan, M.D., Ph.D.
|
| | | | 2,723 | | | | | | — | | | | | $ | 19.30 | | | | | | 9/6/2021 | | |
| | | | | 2,458 | | | | | | — | | | | | $ | 23.10 | | | | | | 12/17/2022 | | |
| | | | | 720 | | | | | | — | | | | | $ | 23.10 | | | | | | 12/17/2022 | | |
| | | | | 1,049 | | | | | | — | | | | | $ | 23.10 | | | | | | 12/17/2022 | | |
| | | | | 1,430 | | | | | | — | | | | | $ | 23.10 | | | | | | 4/16/2023 | | |
| | | | | 2,529 | | | | | | — | | | | | $ | 68.10 | | | | | | 3/18/2024 | | |
| | | | | 466 | | | | | | — | | | | | $ | 110.50 | | | | | | 3/25/2025 | | |
| | | | | 6,600 | | | | | | — | | | | | $ | 45.70 | | | | | | 2/10/2026 | | |
| | | | | 4,500 | | | | | | — | | | | | $ | 43.10 | | | | | | 9/7/2026 | | |
| | | | | 9,584 | | | | | | 416(1) | | | | | $ | 12.40 | | | | | | 2/8/2027 | | |
| | | | | 7,088 | | | | | | 2,912(2) | | | | | $ | 12.80 | | | | | | 2/7/2028 | | |
| | | | | 15,000 | | | | | | — | | | | | $ | 7.10 | | | | | | 9/6/2028 | | |
| | | | | 18,333 | | | | | | 21,667(3) | | | | | $ | 4.39 | | | | | | 2/12/2029 | | |
| | |
Option Awards
|
| |||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
| | | | | — | | | | | | 60,000(4) | | | | | $ | 5.32 | | | | | | 2/11/2030 | | |
Andrew Nichols, Ph.D.
|
| | | | 5,836 | | | | | | — | | | | | $ | 68.10 | | | | | | 3/18/2024 | | |
| | | | | 272 | | | | | | — | | | | | $ | 110.50 | | | | | | 3/25/2025 | | |
| | | | | 778 | | | | | | — | | | | | $ | 110.50 | | | | | | 4/29/2025 | | |
| | | | | 2,600 | | | | | | — | | | | | $ | 45.70 | | | | | | 2/10/2026 | | |
| | | | | 4,000 | | | | | | — | | | | | $ | 43.10 | | | | | | 9/7/2026 | | |
| | | | | 1,300 | | | | | | — | | | | | $ | 57.90 | | | | | | 10/2/2026 | | |
| | | | | 9,584 | | | | | | 416(1) | | | | | $ | 12.40 | | | | | | 2/8/2027 | | |
| | | | | 7,088 | | | | | | 2,912(2) | | | | | $ | 12.80 | | | | | | 2/7/2028 | | |
| | | | | 15,000 | | | | | | — | | | | | $ | 7.10 | | | | | | 9/6/2028 | | |
| | | | | 18,333 | | | | | | 21,667(3) | | | | | $ | 4.39 | | | | | | 2/12/2029 | | |
| | | | | — | | | | | | 60,000(4) | | | | | $ | 5.32 | | | | | | 2/11/2030 | | |
Name
|
| |
Cash
Severance ($)(1) |
| |
Bonus
($)(2) |
| |
COBRA
Continuation ($)(3) |
| |
Value of
Accelerated Vesting of Equity Awards ($)(4) |
| |
Total
($) |
| |||||||||||||||
Jill C. Milne, Ph.D.
Termination without cause or upon resignation with good reason |
| | | | 519,925 | | | | | | 106,816 | | | | | | 21,168 | | | | | | — | | | | | | 647,909 | | |
Termination upon a change in control
|
| | | | 779,887 | | | | | | 106,816 | | | | | | 31,752 | | | | | | — | | | | | | 918,455 | | |
Joanne M. Donovan, M.D., Ph.D.
Termination without cause or upon resignation with good reason |
| | | | 436,497 | | | | | | — | | | | | | 21,168 | | | | | | — | | | | | | 457,665 | | |
Termination upon a change in control
|
| | | | 436,497 | | | | | | — | | | | | | 21,168 | | | | | | — | | | | | | 457,665 | | |
Andrew Nichols, Ph.D.
Termination without cause or upon resignation with good reason |
| | | | 378,958 | | | | | | — | | | | | | 21,168 | | | | | | — | | | | | | 400,126 | | |
Termination upon a change in control
|
| | | | 378,958 | | | | | | — | | | | | | 21,168 | | | | | | — | | | | | | 400,126 | | |
| | |
Series X
Preferred Stock Issued and Outstanding |
| |
Series X
Preferred Stock Issuable Upon Exercise of Warrant |
| |
Common Stock
(as converted) |
| |||||||||
Shares issued in Quellis Acquisition
|
| | | | 50,504 | | | | | | — | | | | | | 50,504,000 | | |
Warrant assumed in Quellis Acquisition
|
| | | | — | | | | | | 2,805 | | | | | | 2,805,000 | | |
February 2021 Financing
|
| | | | 35,573 | | | | | | — | | | | | | 35,573,000 | | |
Total
|
| | | | 86,077 | | | | | | 2,805 | | | | | | 88,882,000 | | |
| | |
Before Reverse
Stock Split |
| |
Reverse Stock
Split Ratio of 1-for-3 |
| |
Reverse Stock
Split Ratio of 1-for-4.5 |
| |
Reverse Stock
Split Ratio of 1-for-6 |
| ||||||||||||
Number of Shares of Common Stock Issued and Outstanding
|
| | | | 23,417,006 | | | | | | 7,805,669 | | | | | | 5,203,779 | | | | | | 3,902,834 | | |
Number of Shares of Common Stock Reserved
for Issuance Pursuant to Outstanding Options and Warrants(1) |
| | | | 10,815,207 | | | | | | 3,605,069 | | | | | | 2,403,379 | | | | | | 1,802,535 | | |
Weighted-Average Exercise Price of Outstanding
Options and Warrants |
| | | $ | 7.31 | | | | | $ | 21.94 | | | | | $ | 32.91 | | | | | $ | 43.89 | | |
Number of Shares of Common Stock Reserved
for Issuance upon Conversion of Series X Preferred Stock |
| | | | 86,077,000 | | | | | | 28,692,333 | | | | | | 19,128,222 | | | | | | 14,346,167 | | |
| | |
Outstanding Stock
Options |
| |
Fully Diluted
Outstanding Shares |
| |
Outstanding Options
as a Percentage of Fully Diluted Outstanding Shares |
| |||||||||
Immediately prior to Quellis Acquisition and February 2021 Financing
|
| | | | 1,332,726 | | | | | | 29,581,911(1) | | | | | | 4.5% | | |
Immediately after Quellis Acquisition and February 2021 Financing
|
| | | | 1,687,720 | | | | | | 122,314,210(2) | | | | | | 1.4% | | |
|
Options Outstanding
|
| |
Shares Available for
Grant |
| |
Weighted Average
Exercise Price of Options Outstanding |
| |
Weighted Average
Remaining Contractual Term of Options Outstanding (Years) |
| |
Aggregate Intrinsic
Value (in thousands) |
| ||||||||||||
|
1,631,322
|
| | | | 1,996,322 | | | | | $ | 9.16 | | | | | | 8.20 | | | | | $ | 879 | | |
Name and Position
|
| |
Number of Shares
Subject to Stock Options |
| |||
Named Executive Officers | | | | | | | |
Jill C. Milne, Ph.D.
President and Chief Executive Officer |
| | | | 1,400,000 | | |
Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer |
| | | | 600,000 | | |
Andrew Nichols, Ph.D.
Chief Scientific Officer |
| | | | 600,000 | | |
Current executive officers who are not Named Executive Officers
|
| | | | 1,600,000 | | |
All current executive officers as a group
|
| | | | 4,200,000 | | |
All current directors who are not executive officers, as a group
|
| | | | 670,000 | | |
All employees who are not executive officers, as a group
|
| | | | 800,000 | | |
Name and Position
|
| |
Number of Shares
Subject to Stock Options(1) |
| |||
Named Executive Officers | | | | | | | |
Jill C. Milne, Ph.D.
President and Chief Executive Officer |
| | | | 346,800 | | |
Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer |
| | | | 146,100 | | |
Andrew Nichols, Ph.D.
Chief Scientific Officer |
| | | | 142,900 | | |
Current executive officers who are not Named Executive Officers
|
| | | | 212,700 | | |
All current executive officers as a group
|
| | | | 848,500 | | |
All current directors who are not executive officers, as a group
|
| | | | 134,659 | | |
All non-employee participants in the plan(2)
|
| | | | 370,016 | | |
All employees who are not executive officers, as a group(3)
|
| | | | 569,465 | | |
Plan category
|
| |
Number of securities
to be issued upon exercise of outstanding stock options, warrants and rights |
| |
Weighted-
average exercise price of outstanding options, warrants and rights |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 1,367,667(1) | | | | | $ | 11.38 | | | | | | 2,085,124(2) | | |
Equity compensation plans not approved by
security holders |
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 1,367,667 | | | | | $ | 11.38 | | | | | | 2,085,124 | | |
| | |
Year Ended
December 31, |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Audit Fees(1)
|
| | | $ | 566,500 | | | | | $ | 582,000 | | |
Audit-Related Fees(2)
|
| | | | — | | | | | | — | | |
Tax Fees(3)
|
| | | | 12,875 | | | | | | 12,875 | | |
All Other Fees(4)
|
| | | | — | | | | | | — | | |
Total
|
| | | $ | 579,375 | | | | | $ | 594,875 | | |
Name of Beneficial Owner
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage of
Shares Beneficially Owned |
| ||||||
5% Stockholders | | | | | | | | | | | | | |
Affiliates of Perceptive Advisors, LLC(1)
|
| | | | 2,476,924 | | | | | | 10.6% | | |
Affiliates of Federated Investment Management Company(2)
|
| | | | 1,562,500 | | | | | | 6.7% | | |
BlackRock, Inc.(3)
|
| | | | 1,166,782 | | | | | | 5.0% | | |
NEOs and Directors | | | | | | | | | | | | | |
Jill C. Milne, Ph.D.(4)
|
| | | | 236,981 | | | | | | * | | |
Joanne M. Donovan, Ph.D., M.D.(5)
|
| | | | 96,893 | | | | | | * | | |
Andrew Nichols, Ph.D.(6)
|
| | | | 89,164 | | | | | | * | | |
Kenneth Bate(7)
|
| | | | 12,297 | | | | | | * | | |
Frederick Callori
|
| | | | — | | | | | | * | | |
Hugh Cole(8)
|
| | | | 5,000 | | | | | | * | | |
Michael D. Kishbauch(9)
|
| | | | 10,850 | | | | | | * | | |
Gregg LaPointe(10)
|
| | | | 10,000 | | | | | | * | | |
Joanne Beck(11)
|
| | | | 10,000 | | | | | | * | | |
Jonathan Violin
|
| | | | — | | | | | | * | | |
All current executive officers and directors as a group (13 persons)(12)
|
| | | | 532,610 | | | | | | 2.2% | | |
| | | | By Order of the Board of Directors | |
|
|
| |
Jill C. Milne, Ph.D.
President and Chief Executive Officer |
|
| RESOLVED: | | | That the first sentence of Article FOURTH of the Restated Certificate of Incorporation of the Corporation be and hereby is deleted in its entirety and the following three paragraphs are inserted in lieu thereof: | |
| | | | “FOURTH: That, effective on the filing of this Certificate of Amendment to Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Effective Time”), a one-for-[ ](1) reverse stock split of the Corporation’s common stock, $0.001 par value per share (the “Common Stock”), shall become effective, pursuant to which each [ ](1) shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the “Reverse Stock Split”). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.001 per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate or book entry position which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the closing price per share of the Common Stock on the Nasdaq Global Market at the close of business on the date of the Effective Time. | |
| | | | Each stock certificate or book entry position that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such | |
| | | | certificate or book entry position have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each person of record holding a certificate or book entry position that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate or book entry position, a new certificate or book entry position evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate or book entry position shall have been reclassified. | |
| | | | The total number of shares of all classes of stock which the Corporation shall have authority to issue is 155,000,000 shares, consisting of (i) 150,000,000 shares of Common Stock and (ii) 5,000,000 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).” | |
| | | | CATABASIS PHARMACEUTICALS, INC. | | |||
| | | | By: | | | | |
| | | | | | |
Jill C. Milne, Ph.D.
President and Chief Executive Officer |
|